Neutron Lifetime Measured with Stored Ultracold Neutrons

The neutron lifetime has been measured by counting the neutrons remaining in a fluid-walled bottle as a function of the duration of storage. Losses of neutrons caused by the wall reflections are eliminated by varying the bottle volume-to-surface ratio. The result obtained is τβ=887.6±3 s

Construction and Performance of a Micro-Pattern Stereo Detector with Two Gas Electron Multipliers

The construction of a micro-pattern gas detector of dimensions 40x10 cm**2 is described. Two gas electron multiplier foils (GEM) provide the internal amplification stages. A two-layer readout structure was used, manufactured in the same technology as the GEM foils. The strips of each layer cross at an effective crossing angle of 6.7 degrees and have a 406 um pitch. The performance of the detector has been evaluated in a muon beam at CERN using a silicon telescope as reference system. The position resolutions of two orthogonal coordinates are measured to be 50 um and 1 mm, respectively. The muon detection efficiency for two-dimensional space points reaches 96%.Comment: 21 pages, 17 figure

UCN anomalous losses and the UCN capture cross-section on material defects

Experimental data shows anomalously large Ultra Cold Neutrons (UCN) reflection losses and that the process of UCN reflection is not completely coherent. UCN anomalous losses under reflection cannot be explained in the context of neutron optics calculations. UCN losses by means of incoherent scattering on material defects are considered and cross-section values calculated. The UCN capture cross-section on material defects is enhanced by a factor of 10^4 due to localization of UCN around defects. This phenomenon can explain anomalous losses of UCN.Comment: 13 pages, 4 figure

Економічні засади покращення інвестиційного клімату України

Розглянуто тенденцію основних прямих та непрямих інвестицій в країну за певний період та виявлено основну низку системних вад економіко - правового середовища, які заважають припливу іноземних інвестицій. Представлені можливі шляхи покращення інвестиційного клімату України.Considered the main trend of direct and indirect investment in the country for a certain period and found a number of major systemic defects economic and legal environment that hinder foreign investment. Courtesy of the main factors that affect the volume of investment, presents possible ways of improving the investment climate in Ukraine

Mass hierarchy discrimination with atmospheric neutrinos in large volume ice/water Cherenkov detectors

Large mass ice/water Cherenkov experiments, optimized to detect low energy (1-20 GeV) atmospheric neutrinos, have the potential to discriminate between normal and inverted neutrino mass hierarchies. The sensitivity depends on several model and detector parameters, such as the neutrino flux profile and normalization, the Earth density profile, the oscillation parameter uncertainties, and the detector effective mass and resolution. A proper evaluation of the mass hierarchy discrimination power requires a robust statistical approach. In this work, the Toy Monte Carlo, based on an extended unbinned likelihood ratio test statistic, was used. The effect of each model and detector parameter, as well as the required detector exposure, was then studied. While uncertainties on the Earth density and atmospheric neutrino flux profiles were found to have a minor impact on the mass hierarchy discrimination, the flux normalization, as well as some of the oscillation parameter (\Delta m^2_{31}, \theta_{13}, \theta_{23}, and \delta_{CP}) uncertainties and correlations resulted critical. Finally, the minimum required detector exposure, the optimization of the low energy threshold, and the detector resolutions were also investigated.Comment: 23 pages, 16 figure

Use of Treponema pallidum PCR in Testing of Ulcers for Diagnosis of Primary Syphilis(1.).

Treponema pallidum PCR (Tp-PCR) has been noted as a valid method for diagnosing syphilis. We compared Tp-PCR to a combination of darkfield microscopy (DFM), the reference method, and serologic testing in a cohort of 273 patients from France and Switzerland and found the diagnostic accuracy of Tp-PCR was higher than that for DFM

Association of Early Norepinephrine Administration With 24-Hour Mortality Among Patients With Blunt Trauma and Hemorrhagic Shock.

Hemorrhagic shock is a common cause of preventable death after injury. Vasopressor administration for patients with blunt trauma and hemorrhagic shock is often discouraged. To evaluate the association of early norepinephrine administration with 24-hour mortality among patients with blunt trauma and hemorrhagic shock. This retrospective, multicenter, observational cohort study used data from 3 registries in the US and France on all consecutive patients with blunt trauma from January 1, 2013, to December 31, 2018. Patients were alive on admission with hemorrhagic shock, defined by prehospital or admission systolic blood pressure less than 100 mm Hg and evidence of hemorrhage (ie, prehospital or resuscitation room transfusion of packed red blood cells, receipt of emergency treatment for hemorrhage control, transfusion of >10 units of packed red blood cells in the first 24 hours, or death from hemorrhage). Blunt trauma was defined as any exposure to nonpenetrating kinetic energy, collision, or deceleration. Statistical analysis was performed from January 15, 2021, to February 22, 2022. Continuous administration of norepinephrine in the prehospital environment or resuscitation room prior to hemorrhage control, according to European guidelines. The primary outcome was 24-hour mortality, and the secondary outcome was in-hospital mortality. The average treatment effect (ATE) of early norepinephrine administration on 24-hour mortality was estimated according to the Rubin causal model. Inverse propensity score weighting and the doubly robust approach with 5 distinct analytical strategies were used to determine the ATE. A total of 52 568 patients were screened for inclusion, and 2164 patients (1508 men [70%]; mean [SD] age, 46 [19] years; median Injury Severity Score, 29 [IQR, 17-36]) presented with acute hemorrhage and were included. A total of 1497 patients (69.1%) required emergency hemorrhage control, 128 (5.9%) received a prehospital transfusion of packed red blood cells, and 543 (25.0%) received a massive transfusion. Norepinephrine was administered to 1498 patients (69.2%). The 24-hour mortality rate was 17.8% (385 of 2164), and the in-hospital mortality rate was 35.6% (770 of 2164). None of the 5 analytical strategies suggested any statistically significant association between norepinephrine administration and 24-hour mortality, with ATEs ranging from -4.6 (95% CI, -11.9 to 2.7) to 2.1 (95% CI, -2.1 to 6.3), or between norepinephrine administration and in-hospital mortality, with ATEs ranging from -1.3 (95% CI, -9.5 to 6.9) to 5.3 (95% CI, -2.1 to 12.8). The findings of this study suggest that early norepinephrine infusion was not associated with 24-hour or in-hospital mortality among patients with blunt trauma and hemorrhagic shock. Randomized clinical trials that study the effect of early norepinephrine administration among patients with trauma and hypotension are warranted to further assess whether norepinephrine is safe for patients with hemorrhagic shock

The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.

OBJECTIVES: To describe disease characteristics and treatment modalities in a multidisciplinary cohort of systemic lupus erythematosus (SLE) patients in Switzerland. METHODS: Cross-sectional analysis of 255 patients included in the Swiss SLE Cohort and coming from centres specialised in Clinical Immunology, Internal Medicine, Nephrology and Rheumatology. Clinical data were collected with a standardised form. Disease activity was assessed using the Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI), an integer physician's global assessment score (PGA) ranging from 0 (inactive) to 3 (very active disease) and the erythrocyte sedimentation rate (ESR). The relationship between SLE treatment and activity was assessed by propensity score methods using a mixed-effect logistic regression with a random effect on the contributing centre. RESULTS: Of the 255 patients, 82% were women and 82% were of European ancestry. The mean age at enrolment was 44.8 years and the median SLE duration was 5.2 years. Patients from Rheumatology had a significantly later disease onset. Renal disease was reported in 44% of patients. PGA showed active disease in 49% of patients, median SLEDAI was 4 and median ESR was 14 millimetre/first hour. Prescription rates of anti-malarial drugs ranged from 3% by nephrologists to 76% by rheumatologists. Patients regularly using anti-malarial drugs had significantly lower SELENA-SLEDAI scores and ESR values. CONCLUSION: In our cohort, patients in Rheumatology had a significantly later SLE onset than those in Nephrology. Anti-malarial drugs were mostly prescribed by rheumatologists and internists and less frequently by nephrologists, and appeared to be associated with less active SLE

PMT gain calibration and monitoring based on highly compressed hit information in KM3NeT

The cubic-kilometre neutrino telescope, consisting of large-scale 3D-arrays of photomultiplier tubes (PMTs) currently under construction on the Mediterranean seabed, relies on accurate calibration procedures in order to answer its science goals. These proceedings present an overview of a novel gain calibration method based on highly compressed PMT hit information. In particular, it is shown that the PMT gains can be tuned to within 2% of the nominal value, based on the measured time-over-threshold.Article signat per 297 autors/es: M.Ageron, S. Aiello, A. Albert, M. Alshamsi, S. Alves Garre, Z. Aly, A. Ambrosone, F. Ameli, M. Andre, G. Androulakis, M. Anghinolfi, M. Anguita, G. Anton, M. Ardid, S. Ardid, W. Assal, J. Aublin, C. Bagatelas, B. Baret, S. Basegmez du Pree, M. Bendahman, F. Benfenati, E. Berbee, A. M. van den Berg, V. Bertin, S. Beurthey, V. van Beveren, S. Biagi, M. Billault, M. Bissinger, M. Boettcher, M. Bou Cabo, J. Boumaaza, M. Bouta, C. Boutonnet, G. Bouvet, M. Bouwhuis, C. Bozza, H.Brânzas, R. Bruijn, J. Brunner, R. Bruno, E. Buis, R. Buompane, J. Busto, B. Caiffi, L. Caillat, D. Calvo, S. Campion, A. Capone, H. Carduner, V. Carretero, P. Castaldi, S. Celli;, R. Cereseto, M. Chabab, C. Champion, N. Chau, A. Chen, S. Cherubini, V. Chiarella, T. Chiarusi, M. Circella, R. Cocimano, J. A. B. Coelho, A. Coleiro, M. Colomer Molla, S. Colonges, R. Coniglione, A. Cosquer, P. Coyle, M. Cresta, A. Creuso, A. Cruz, G. Cuttone, A. D’Amico, R. Dallier, B. De Martino, M. De Palma, I. Di Palma, A. F. Díaz, D. Diego- Tortosa, C. Distefano, A. Domi, C. Donzaud, D. Dornic, M. Dörr, D. Drouhin, T. Eberl, A. Eddyamoui, T. van Eeden, D. van Eijk, I. El Bojaddaini, H. Eljarrari, D. Elsaesser, A. Enzenhöfer, V. Espinosa, P. Fermani, G. Ferrara, M. D. Filipovic, F. Filippini, J. Fransen, L. A. Fusco, D. Gajanana, T. Gal, J. García Méndez, A. Garcia Soto, E. Garçon, F. Garufi, C. Gatius, N. Geißelbrecht, L. Gialanella, E. Giorgio, S. R. Gozzini, R. Gracia, K. Graf, G. Grella, D. Guderian, C. Guidi, B. Guillon, M. Gutiérrez, J. Haefner, S. Hallmann, H. Hamdaoui, H. van Haren, A. Heijboer, A. Hekalo, L. Hennig, S. Henry, J. J. Hernández-Rey, J. Hofestädt, F. Huang,W. Idrissi Ibnsalih, A. Ilioni, G. Illuminati, C.W. James, D. Janezashvili, P. Jansweijer, M. de Jong, P. de Jong, B. J. Jung, M. Kadler, P. Kalaczynski, O. Kalekin,U. F. Katz, F. Kayzel, P.Keller, N. R. Khan Chowdhury, G. Kistauri, F. van der Knaap, P. Kooijman, A. Kouchner, M. Kreter, V. Kulikovskiy, M. Labalme, P. Lagier, R. Lahmann, P. Lamare, M. Lamoureux, G. Larosa, C. Lastoria, J. Laurence, A. Lazo, R. Le Breton, E. Le Guirriec, S. Le Stum, G. Lehaut, O. Leonardi, F. Leone, E. Leonora, C. Lerouvillois, J. Lesrel, N. Lessing, G. Levi, M. Lincetto, M. Lindsey Clark, T. Lipreau, C. LLorens Alvarez, A. Lonardo, F. Longhitano, D. Lopez-Coto, N. Lumb, L. Maderer, J. Majumdar, J. Manczak, A. Margiotta, A. Marinelli, A. Marini, C. Markou, L. Martin, J. A. Martínez-Mora, A. Martini, F. Marzaioli, S. Mastroianni, K.W. Melis, G. Miele, P. Migliozzi, E. Migneco, P. Mijakowski, L. S. Miranda, C. M. Mollo, M. Mongelli, A. Moussa, R. Muller, P. Musico, M. Musumeci, L. Nauta, S. Navas, C. A. Nicolau, B. Nkosi, B. Ó Fearraigh, M. O’Sullivan, A. Orlando, G. Ottonello, S. Ottonello, J. Palacios González5, G. Papalashvili, R. Papaleo, C. Pastore, A. M. Paun, G. E. Pavalas, G. Pellegrini, C. Pellegrino, M. Perrin-Terrin, V. Pestel, P. Piattelli, C. Pieterse, O. Pisanti, C. Poirè, V. Popa, T. Pradier, F. Pratolongo, I. Probst, G. Pühlhofer, S. Pulvirenti, G. Quéméner, N. Randazzo, A. Rapicavoli, S. Razzaque, D. Real, S. Reck, G. Riccobene, L. Rigalleau, A. Romanov, A. Rovelli, J. Royon, F. Salesa Greus, D. F. E. Samtleben, A. Sánchez Losa, M. Sanguineti, A. Santangelo, D. Santonocito, P. Sapienza, J. Schmelling, J. Schnabel, M. F. Schneider, J. Schumann, H. M. Schutte, J. Seneca, I. Sgura, R. Shanidze, A. Sharma, A. Sinopoulou, B. Spisso, M. Spurio, D. Stavropoulos, J. Steijger, S. M. Stellacci, M. Taiuti, F. Tatone, Y. Tayalati, E. Tenllado, D. Tézier, T. Thakore, S. Theraube, H. Thiersen, P. Timmer, S. Tingay, S. Tsagkli, V. Tsourapis, E. Tzamariudaki, D. Tzanetatos, C. Valieri, V. Van Elewyck, G. Vasileiadis, F. Versari, S. Viola, D. Vivolo, G. de Wasseige, J.Wilms, R.Wojaczynski, E. deWolf, T. Yousfi, S. Zavatarelli, A. Zegarelli, D. Zito, J. D. Zornoza, J. Zúñiga, N. ZywuckaPostprint (published version